首页> Cancer discovery> Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

导出 OA

翻译打印收藏纠错

第一作者： Simon,Linder

第一单位： Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

作者： Simon,Linder ^[1] ; Marlous,Hoogstraat ^[2] ; Suzan,Stelloo ^[1] ; Nils,Eickhoff ^[1] ; Karianne,Schuurman ^[1] ; Hilda,de Barros ^[3] ; Maartje,Alkemade ^[4] ; Elise M,Bekers ^[5] ; Tesa M,Severson ^[2] ; Joyce,Sanders ^[5] ; Chia-Chi Flora,Huang ^[6] ; Tunc,Morova ^[6] ; Umut Berkay,Altintas ^[7] ; Liesbeth,Hoekman ^[8] ; Yongsoo,Kim ^[9] ; Sylvan C,Baca ^[10] ; Martin,Sjöström ^[11] ; Anniek,Zaalberg ^[1] ; Dorine C,Hintzen ^[12] ; Jeroen,de Jong ^[5] ; Roelof J C,Kluin ^[13] ; Iris,de Rink ^[13] ; Claudia,Giambartolomei ^[14] ; Ji-Heui,Seo ^[15] ; Bogdan,Pasaniuc ^[14] ; Maarten,Altelaar ^[16] ; René H,Medema ^[12] ; Felix Y,Feng ^[17] ; Amina,Zoubeidi ^[18] ; Matthew L,Freedman ^[10] ; Lodewyk F A,Wessels ^[19] ; Lisa M,Butler ^[20] ; Nathan A,Lack ^[21] ; Henk,van der Poel ^[22] ; Andries M,Bergman ^[23] ; Wilbert,Zwart ^[24]

作者单位： Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[1] Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[2] Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[3] Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[4] Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[5] Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada. ^[6] School of Medicine, Koç University, Istanbul, Turkey.;Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey. ^[7] Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[8] Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, the Netherlands. ^[9] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.;The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts. ^[10] Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. ^[11] Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[12] Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[13] Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.;Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. ^[14] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ^[15] Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, the Netherlands. ^[16] Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.;Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.;Department of Urology, University of California, San Francisco, San Francisco, California. ^[17] Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.;Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. ^[18] Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Faculty of EEMCS, Delft University of Technology, Delft, the Netherlands. ^[19] Freemasons Centre for Male Health and Wellbeing, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.;South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. ^[20] Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.;School of Medicine, Koç University, Istanbul, Turkey.;Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey. ^[21] Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Department of Urology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. ^[22] Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ^[23] Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands. ^[24]